SCHEMBL6421067

SCHEMBL6421067

NN=C(c1ccccc1O)c1nc2nonc2nc1Nc1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
TP53 P04637 2/20 0.44
MEN1 O00255 7/20 0.40
KMT2A Q03164 7/20 0.40
RAB9A P51151 1/20 0.40
KDM4E B2RXH2 3/20 0.35
GAA P10253 2/20 0.34
DHODH Q02127 1/20 0.34
RECQL P46063 1/20 0.34
POLB P06746 3/20 0.34
MAPK9 P45984 1/20 0.34
MAPK10 P53779 1/20 0.34
MAPK1 P28482 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ABCG2 Q9UNQ0 1/20 0.33
EGFR P00533 1/20 0.33
KDR P35968 1/20 0.33
NTRK1 P04629 1/20 0.32
ALK Q9UM73 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6421060 1.00 MAPT (0.44) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL6432637 0.91 TP53 (0.35) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL6432628 0.91 TP53 (0.35) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL6417241 0.87 SMN1; SMN2 (0.43) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL6417228 0.87 SMN1; SMN2 (0.43) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL6419775 0.86 MAPT (0.39) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL6419767 0.86 MAPT (0.39) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL6418425 0.85 P2RX1 (0.41) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL6418390 0.85 MAPT (0.41) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL6418380 0.85 MAPT (0.41) MAPTSMN1; SMN2TP53MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885SMN1; SMN2 4369/4885TP53 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.